Can G-CSF Cause Leukemia in Hematopoietic Stem Cell Donors?

被引：38

作者：

Avalos, Belinda R. ^{[2
]}

Lazaryan, Aleksandr ^{[1
]}

Copelan, Edward A. ^{[1
]}

机构：

[1] Cleveland Clin, Cleveland, OH 44195 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 12期

关键词：

G-CSF; Peripheral blood progenitor cell mobilization; Stem cell donors; COLONY-STIMULATING-FACTOR; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; SEVERE CONGENITAL NEUTROPENIA; ADVERSE DRUG EVENTS; FACTOR-RECEPTOR; BONE-MARROW; FOLLOW-UP; MYELODYSPLASTIC SYNDROME; HEALTHY-INDIVIDUALS;

D O I：

10.1016/j.bbmt.2011.07.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A large majority of allogeneic hematopoietic stem cell donations are achieved using granulocyte-colony stimulating factor (G-CSF). G-CSF use has been associated with later development of myelodysplastic syndromes/acute myelogenous leukemia (MDS/AML) in several clinical circumstances. Although clinical data to date have failed to identify any increased incidence of MDS/AML in G-CSF mobilized donors, the quality of these data are insufficient to exclude a long-term risk. Physicians should explain the potential risk to donors, and where appropriate, offer donors the option of marrow donation. Biol Blood Marrow Transplant 17: 1739-1746 (2011) (C) 2011 American Society for Blood and Marrow Transplantation

引用

页码：1739 / 1746

页数：8

共 94 条

[1] Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim:: no evidence of increased risk of leukemia development [J].